Combination of inflammatory and vascular markers in the febrile phase of dengue is associated with more severe outcomes

NguyenLamVuong[email protected]1 2
PhungKhanhLam1 2
DamienKengYenMing3
HuynhThiLeDuyen1
NguyetMinhNguyen1
DongThiHoaiTam1
KienDuongThiHue1
NguyenVVChau4
NgounChanpheaktra5
LucyChaiSeeLum6
ErnestoPleités7
CameronPSimmons8 9
KerstinDRosenberger10
ThomasJaenisch10 11
DavidBell12
NathalieAcestor13
ChristineHalleux14
PieroLOlliaro8
BridgetAWills1 8
RonaldBGeskus1 8
SophieYacoub[email protected]1 8

Oxford University Clinical Research Unit (OUCRU)
Ho Chi Minh CityViet Nam
University of Medicine and Pharmacy at Ho Chi Minh City
Ho Chi Minh CityViet Nam
Department of Infectious Disease, Imperial College London
LondonUnited Kingdom
Hospital for Tropical Diseases
Ho Chi Minh cityViet Nam
Angkor Hospital for Children
Siem ReapCambodia
University of Malaya Medical Centre
Kuala LumpurMalaysia
Hospital Nacional de Niños Benjamin Bloom
San SalvadorEl Salvador
Centre for Tropical Medicine and Global health, Nuffield Department of Clinical Medicine, University of Oxford
OxfordUnited Kingdom
Institute for Vector-Borne Disease, Monash University
ClaytonAustralia
Section Clinical Tropical Medicine, Department for Infectious Diseases, Heidelberg University Hospital
HeidelbergGermany
Heidelberg Institute of Global Health (HIGH), Heidelberg University Hospital
HeidelbergGermany
Independent consultant
IssaquahUnited States
Consultant, Intellectual Ventures, Global Good Fund
BellevueUnited States
UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization
GenevaSwitzerland

2021-06-22

Research Article

Medicine
Microbiology and Infectious Disease

dengue
biomarkers
prognostic
Virus

publisher-id67460
doi10.7554/eLife.67460
elocation-ide67460

Abstract

Early identification of severe dengue patients is important regarding patient management and resource allocation. We investigated the association of 10 biomarkers (VCAM-1, SDC-1, Ang-2, IL-8, IP-10, IL-1RA, sCD163, sTREM-1, ferritin, CRP) with the development of severe/moderate dengue (S/MD).

We performed a nested case-control study from a multi-country study. A total of 281 S/MD and 556 uncomplicated dengue cases were included.

On days 1–3 from symptom onset, higher levels of any biomarker increased the risk of developing S/MD. When assessing together, SDC-1 and IL-1RA were stable, while IP-10 changed the association from positive to negative; others showed weaker associations. The best combinations associated with S/MD comprised IL-1RA, Ang-2, IL-8, ferritin, IP-10, and SDC-1 for children, and SDC-1, IL-8, ferritin, sTREM-1, IL-1RA, IP-10, and sCD163 for adults.

Our findings assist the development of biomarker panels for clinical use and could improve triage and risk prediction in dengue patients.

This study was supported by the EU's Seventh Framework Programme (FP7-281803 IDAMS), the WHO, and the Bill and Melinda Gates Foundation.

Introduction

Dengue is the most common arboviral disease to affect humans globally. In 2019, the World Health Organization (WHO) identified dengue as one of the top 10 threats to global health 50World Health Organization2019. Transmission occurs in 129 countries, with an estimated 3.9 billion people being at risk 51World Health Organization2020. Over the last two decades, the number of reported cases per year has increased more than eight-fold 51World Health Organization2020, and in 2020 the annual number of dengue virus (DENV) infections was estimated to be 105 million, with 51 million cases being clinically apparent 4Cattarino et al.2020. With climate change, increased travel and urbanization, this rise is forecasted to continue over the coming decades 48Whitehorn and Yacoub201952Yacoub et al.2011. Despite the large disease burden, there is still no specific treatment for dengue, and the only licensed vaccine is recommended only in individuals with earlier dengue infection 31Redoni et al.2020.

In many dengue-endemic settings, seasonal epidemics can rapidly overwhelm fragile health systems. Although most symptomatic dengue infections are self-limiting, a small proportion of patients develop complications, most of which manifest at around 4–6 days from symptom onset. Thus, large numbers of patients require regular assessments to identify complications should they arise. The accurate and early identification of such patients, particularly within the first 3 days of illness in the febrile phase, should allow for appropriate care to be provided and potentially increase health system effectiveness. Although the 2009 WHO dengue guidelines set out specific warning signs for use in patient triage, utility of these guidelines at identifying those at risk for complications remains limited 21Morra et al.2018.

The pathogenesis of dengue involves a complex interplay between viral factors and the host response. It is hypothesized that an excessive immune response acting through inflammatory mediators can lead to the observed manifestations of bleeding, shock, and organ dysfunction. Studies have shown that in secondary infections, adaptive immune activation can result in high circulating levels of plasma cytokines and chemokines 15Katzelnick et al.201719Midgley et al.201137Screaton et al.2015. Binding of viral NS1 protein onto endothelial cells can act in concert with vasoactive substances, cytokines, and chemokines, to result in endothelial activation and glycocalyx disruption, and these processes likely underlie the increased vascular permeability and coagulopathy 18McBride and Khanh Lam202020Modhiran et al.201540St John et al.2013.

The role of blood biomarkers in predicting severe outcomes has been investigated in many studies, but mostly at later time-points or at hospital admission and many of these biomarkers either peak too late in the disease course or have too short a half-life to be clinically useful 1Ab-Rahman et al.201613John et al.201523Oliveira et al.201727Puerta-Guardo et al.201930Rathore et al.202032Robinson and Einav202034S S et al.201738Soo et al.201744Vasey et al.202055Yacoub et al.201754Yacoub et al.201656Yong et al.2017. Acknowledging these characteristics, we selected 10 candidate biomarkers from the vascular, immunological, and inflammatory pathways with good evidence supporting their involvement in the pathogenesis of dengue infection – focusing on those likely to be increased early in the disease course. We included vascular cell adhesion molecule-1 (VCAM-1), syndecan-1 (SDC-1), and angiopoietin-2 (Ang-2) because they represent endothelial activation and glycocalyx integrity 7Han et al.201917Mapalagamage et al.202041Suwarto et al.201753Yacoub et al.2016. For markers of immune activation, we measured interleukin-8 (IL-8) and interferon gamma-induced protein-10 (IP-10) as these are associated with disease severity 23Oliveira et al.201724Pandey et al.201529Rathakrishnan et al.2012, and IL-1 receptor antagonist (IL-1RA), soluble cluster of differentiation 163 (sCD163), and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as these are activation markers of monocytes and macrophages, the major targets for dengue replication 1Ab-Rahman et al.201613John et al.201534S S et al.2017. For markers of general inflammation, we included ferritin and C-reactive protein (CRP) 1Ab-Rahman et al.20166Finkelstein et al.202022Mukherjee and Tripathi202039Soundravally et al.201545Vuong et al.2020.

The aims of this study were: (1) to investigate the association of these ten biomarkers with development of more severe dengue outcomes, (2) to find the best combination of biomarkers associated with more severe dengue outcomes. The results of the second aim could help in developing multiplex panels for use in outpatient settings to rapidly identify patients who require hospitalization.

Materials and methods

Study design

We conducted a nested case-control study using the samples and clinical information from a large multi-country observational study named ‘Clinical evaluation of dengue and identification of risk factors for severe disease’ (IDAMS study, NCT01550016) 12Jaenisch et al.2016. The IDAMS study and the blood sample analysis were approved by the Scientific and Ethics Committees of all study sites (Hospital for Tropical Diseases [Ho Chi Minh City, Vietnam] Ref No 03/HDDD-05/01/2018; Angkor Hospital for Children [Siem Reap, Cambodia] Ref No 0146/18-AHC; University of Malaya Medical Centre [Kuala Lumpur, Malaysia] Ref No 201865–6361) and by the Oxford Tropical Research Ethics Committee (OxTREC Ref No 502–18). There were 7428 participants in eight countries across Asia and Latin America enrolled in the IDAMS study. Patients were eligible for inclusion if they were aged 5 years or older, had fever or history of fever for less than 72 hr, and had symptoms consistent with dengue, with no features strongly suggestive of another disease. Participants were followed daily with a standard schedule of clinical examination and blood samples. Individual management (including hospitalization) was in accordance with routine practice at each study site. All diagnostic samples were processed and stored following specific protocols, and later transferred to designated sites for diagnostic testing in order to ensure consistency. Laboratory-confirmed dengue was defined by a positive reverse transcriptase polymerase chain reaction (RT-PCR) or a positive NS1 enzyme-linked immunosorbent assay (ELISA) result. Immune status was classified based on capture IgG results on paired samples. A probable primary infection was defined by two negative IgG results on two consecutive specimens taken at least 2 days apart, with at least one specimen obtained during the convalescent phase (after illness day 5). A probable secondary infection was defined by a positive IgG result identified during either or both the febrile and convalescent phases. In all other cases with the absence of suitable specimens at the appropriate time points immune status was classified as inconclusive. Each participant was given an overall severity grade (severe, moderate, or uncomplicated dengue), using all available information and a grading system in line with current guidelines and recommendations to classify clinical endpoints in dengue clinical trials 43Tomashek et al.2018.

Study population

Of the 2694 laboratory-confirmed dengue cases in the IDAMS study, 38 and 266 cases were classified as severe and moderate dengue respectively. For this study, we selected all severe and moderate cases from five study sites in four countries (Vietnam, Cambodia, Malaysia, and El Salvador), as residual plasma from these countries’ sample sets was available at the Oxford University Clinical Research Unit (OUCRU) in Ho Chi Minh City, Vietnam. For the control group, we selected patients with uncomplicated dengue with similar geographic and demographic characteristics at a 2:1 ratio. In total 281 cases and 556 controls were included in the analysis (Figure 1).

Study flowchart.

*The IDAMS study was performed in eight countries across Asia and Latin America. For this study, we selected cases in four countries (Vietnam, Cambodia, Malaysia, and El Salvador) as the blood samples were stored at the laboratory of the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam.

Laboratory evaluation (details in Appendix 1)

The biomarkers were measured at two time points: at enrollment (illness day 1–3) and after recovery (day 10–31 post-symptom onset), if available. Eight biomarkers (CRP and ferritin excepted) were combined in a premixed magnetic bead panel (Cat No. LXSAHM; R and D). CRP was measured using a separate commercial magnetic bead panel (Cat. No. HCVD3MAG-67K; EMD Millipore Corporation). These panels were analyzed using the Luminex200 analyzer with the Luminex calibration (Cat. No. LX200-CAL-K25) and verification kits (Cat. No. LX200-CON-K25). Ferritin was measured using the Human Ferritin ELISA kit (Cat. No. ARG80501, Arigo). All tests were done according to the manufacturer’s specifications.

Study endpoints (details in Appendix 2)

The primary endpoint was combined severe and moderate dengue (S/MD), defined by the development of severe or moderate grades of any of the following – plasma leakage, haemorrhage, or organ impairment (including neurologic, hepatic, or cardiac involvement) (Appendix 2—table 1). We combined severe and moderate dengue to form the primary endpoint (S/MD) as severe dengue events were rare; this combined endpoint is relevant to clinical practice since the moderate group is likely to develop complications and therefore may also require medical intervention and hospitalization. We studied three secondary endpoints: severe dengue alone, severe dengue or dengue with warning signs according to the 2009 WHO classification, and hospitalization. These endpoints were selected as they also reflect the disease burden and severity and are generalizable across different settings. The decision to hospitalize was based only on clinical judgement and local guidelines particular to each study site, without use of any biomarker information.

Statistical analysis (details in Appendix 3)

Plasma levels of all biomarkers were transformed to the base-2 logarithm (log-2) before analysis as a right skewed distribution was apparent. We used a logistic regression model for all endpoints. We investigated the non-linear effects of all biomarkers and age on the endpoints, using restricted cubic splines with three knots at the 10th, 50th, and 90th percentiles.

For the first aim, that is to investigate the association of all biomarkers with the primary and secondary endpoints, we performed two different analyses: (1) fitting models for each biomarker separately (‘single models’) and (2) fitting models including all biomarkers together (‘global models’). In the ‘single models’ for a particular biomarker, only that biomarker along with age and their interaction were included, whereas in the ‘global models’ all the biomarkers along with their interactions with age were included. We performed the ‘global model’ in order to investigate the influence of the biomarkers when considering them together and this was also the initial step to develop models for the second aim. Results are reported as odds ratio (OR) and presented graphically.

For the second aim to find the best combination of biomarkers associated with the primary endpoint, we built upon the results from the first aim to fit separate models for children and adults (<15 versus ≥15 years of age), as differences were apparent by age. We used variable selection based on the ‘best subset’ approach 9Hastie et al.201711Hocking and Leslie1967. Briefly, this approach screened all possible combinations of biomarkers and selected the best based on the Akaike information criterion (AIC). We chose AIC as a ranking measurement because it quantifies goodness of fit, while guarding against over-fitting. The marker combination with the lowest AIC was taken as the best. From an ‘initial model’ including all biomarkers, we determined the best general combination and the best combinations of 2, 3, 4, and 5 biomarkers. We then performed a bootstrap procedure to check the robustness (stability) of the selected models. For this we resampled 1000 times with replacement from the original dataset. For each of these 1000 bootstrap samples, we performed the ‘best subset’ procedure similar to above to determine the best combination. We calculated the selection frequency of each marker combination over the 1000 samples. The frequency of the combination that was selected when using the original dataset in relation to the other combinations characterizes robustness of the selection.

We carried out several sensitivity analyses. First, we fitted the single and global models taking into account potential differences between serotypes by including serotype variable along with its interaction with the biomarkers. Second, we included viremia (viral RNA measured by RT-PCR) levels as an additional biomarker and performed the single model, global model and best subset procedure. Higher viremia levels have been associated with worse disease outcomes; however, viral load was not considered in the main analysis as the focus was on host markers with the potential for combining in a biomarker rapid test.

All analyses were done using the statistical software R version 3.6.3 28R Core Development Team2020 and the packages ‘rms’ 8Harrell Jr2019, ‘MuMIn’ 2Bartoń2020 and ‘ggplot2’ 49Wickham2016. The code is available on GitHub (47Vuong2021; copy archived at swh:1:rev:847d8e0f564eeb3f075b443205fb3384598bc2b4).

Results

Patient characteristics

The majority of the patients were from Vietnam (640 cases, 76%). Median (1st, 3rd quartiles) age of the case and control groups were 12 (9, 22) and 16 (10, 24) years. Among the S/MD group, 127 cases (45%) were children and 154 cases (55%) were adults. Male gender was predominant (60% and 54% in the case and control groups respectively). Serotype distribution was similar between the S/MD and control groups, with DENV-1 predominating (42%), particularly in children (48%). Host immune status however differed: there was a higher proportion of secondary infections in the S/MD group compared with controls (78% versus 64%, respectively) and this was consistent in both children and adults. The S/MD had a slightly lower percentage of obese patients than the control group (10% versus 14%). As expected, hospitalization was more common in the S/MD group (57% versus 31%) (Table 1). Overall, 38 patients developed severe dengue, most were severe plasma leakage (33/38 cases, 87%) and 29/38 (76%) were children. Most of the moderate dengue cases were plasma leakage and/or hepatic involvement (Appendix 4—table 1).

General setup

print("Load data and general setup")

# Load packages
library(tidyverse)
library(gtsummary) # need to install package 'flextable'
library(rms)
library(MuMIn) # for best subset selection
library(facetscales) # need to install package 'facetscales' from devtools::install_github("zeehio/facetscales")
source("Elife ERA functions.R") # to include my functions
options(gtsummary.tbl_summary.percent_fun = function(x) sprintf(x * 100, fmt='%1.0f')) # to report percentages without decimal
options(knitr.kable.NA = '') # to set NA to '' in kable results
theme_set(theme_bw()) # I love black & white theme
options(na.action = "na.fail") # for 'dredge' function [MuMIn]

# Load full data
dat0 <- read_csv("Dengue_Biomarkers_data_27Jul2021.csv") %>%
  mutate(group2 = factor(sev.or.inte, levels=c(0,1), labels=c("Uncomplicated dengue","Severe/moderate dengue")),
         Country = as.factor(Country),
         Serotype = as.factor(Serotype),
         Serology = factor(Serology, levels = c("Probable primary", "Probable secondary", "Inconclusive")),
         WHO2009 = factor(WHO2009, levels = c("Mild dengue", "Dengue with warning signs", "Severe dengue", "Unknown")))

# Data at enrollment (for Table 1 & Appendix 4-table 1)
dat <- dat0 %>% filter(Time == "Enrolment")

# Data at enrollment for models
## with inverse probability weights (IPW) for inclusion probability by countries (for the analysis of secondary outcomes)
## transform the biomarker's levels to log-2 and viremia to log-10
## set all biomarker's levels under the limit of detection (u...=1) to the limit of detection
dat1 <- dat %>%
  mutate(age15 = factor(age15, levels=c("No","Yes"), labels=c("Under 15","15 and above")),
         Serotype = ifelse(Serotype=="Unknown", NA, as.character(Serotype)),
         Serotype = ifelse(Serotype=="DENV-1", 1, 2),
         Serotype2 = Serotype, # for getting results for Appendix5-tables 1, 2
         Serotype = factor(Serotype, levels=c(1,2), labels=c("DENV-1","Others")), # set Serotype to DENV-1 and others
         ipw = ifelse(sev.or.inte==1, 1,
                      ifelse(Country=="Vietnam", (1505-204)/436,
                             ifelse(Country=="Malaysia", (259-29)/58,
                                    ifelse(Country=="El Salvador", (306-18)/23,
                                           ifelse(Country=="Cambodia", (302-30)/39, NA))))),
         ipwsd = ipw * 837/2372,
         VCAM = ifelse(uVCAM==1, log2(0.028), log2(VCAM1)),
         SDC = log2(SDC1),
         Ang = ifelse(uAng==1, log2(17.1), log2(Ang2)),
         IL8 = ifelse(uIL8==1, log2(1.8), log2(IL8)),
         IP10 = ifelse(uIP10==1, log2(1.18), log2(IP10)),
         IL1RA = ifelse(uIL1RA==1, log2(18), log2(IL1RA)),
         CD163 = log2(CD163),
         TREM = ifelse(uTREM==1, log2(10.65), log2(TREM1)),
         Fer = log2(Fer),
         CRP = log2(CRP), 
         Vir = log10(Viremia)) %>%
  select(Code, Age, age15, Serotype, Serotype2, sev.or.inte, sev.only, sev.or.ws, hospital, VCAM, SDC, Ang, IL8, IP10, IL1RA, CD163, TREM, Fer, CRP, Vir, uVCAM, uAng, uIL8, uIP10, uCD163, uTREM, uVir, ipw, ipwsd)

dat1c <- dat1 %>% filter(age15 == "Under 15") ## Data for children
dat1a <- dat1 %>% filter(age15 == "15 and above") ## Data for adults

# Set references for calculating the ORs and 95% CIs
ref0 <- c(median(dat1$VCAM), median(dat1$SDC), median(dat1$Ang), median(dat1$IL8), median(dat1$IP10), median(dat1$IL1RA), median(dat1$CD163), median(dat1$TREM), median(dat1$Fer), median(dat1$CRP))

# Create data for plotting biomarkers (for Figure 2 & Appendix 4-figure 1)
## Enrollment
tmp1 <- dat0 %>%
  filter(Time == "Enrolment") %>%
  select(Code, group2, Day, Daygr, VCAM1, SDC1, Ang2, IL8, IP10, IL1RA, CD163, TREM1, Fer, CRP) %>%
  gather(., "Biomarker", "Result", 5:14)

## Follow up
tmp2 <- dat0 %>%
  filter(Time == "Follow up") %>%
  select(Code, group2, Day, Daygr, VCAM1, SDC1, Ang2, IL8, IP10, IL1RA, CD163, TREM1, Fer, CRP) %>%
  gather(., "Biomarker", "Result", 5:14)

## Merge long data for biomarkers
dat_plot <- bind_rows(tmp1, tmp2) %>%
  mutate(Daygr = factor(Daygr, levels = c("Day 1", "Day 2", "Day 3", "Day 10-20", "Day >20"),
                        labels = c("1", "2", "3", "10-20", ">20")),
         Biomarker = factor(Biomarker, levels=c("VCAM1", "SDC1", "Ang2", "IL8", "IP10", "IL1RA", "CD163", "TREM1", "Fer", "CRP"), 
                            labels=c("VCAM-1 (ng/ml)", "SDC-1 (pg/ml)", "Ang-2 (pg/ml)", "IL-8 (pg/ml)", "IP-10 (pg/ml)", 
                                     "IL-1RA (pg/ml)", "sCD163 (ng/ml)", "sTREM-1 (pg/ml)", "Ferritin (ng/ml)", "CRP (mg/l)")))

Table 1.

# All patients
t1 <- dat %>%
  select(group2, Country, Age, Sex, Day, Serotype, Serology, Obesity, Diabetes, WHO2009, hospital) %>%
  tbl_summary(by = group2,
              statistic = list(all_continuous() ~ "{median} ({p25}, {p75})", all_categorical() ~ "{n} ({p})"),
              value = list(Sex ~ "Male"),
              digits = list(all_continuous() ~ c(0,0)),
              label = list(Age ~ "Age (years)", Sex ~ "Gender male", Day ~ "Illness day at enrolment",
                           Serology ~ "Immune status", WHO2009 ~ "WHO 2009 classification", hospital ~ "Hospitalization")) %>%
  add_stat_label(label = c(all_categorical() ~ "n (%)", Age ~ "median (1st, 3rd quartiles)")) %>%
  modify_header(label = "", stat_by = "**{level} (N={n})**")

# Children (<15 years of age)
t2 <- dat %>%
  filter(age15=="No") %>%
  select(group2, Country, Age, Sex, Day, Serotype, Serology, Obesity, Diabetes, WHO2009, hospital) %>%
  tbl_summary(by = group2,
              statistic = list(all_continuous() ~ "{median} ({p25}, {p75})", all_categorical() ~ "{n} ({p})"),
              value = list(Sex ~ "Male"),
              digits = list(all_continuous() ~ c(0,0)),
              label = list(Age ~ "Age (years)", Sex ~ "Gender male", Day ~ "Illness day at enrolment",
                           Serology ~ "Immune status", WHO2009 ~ "WHO 2009 classification", hospital ~ "Hospitalization")) %>%
  add_stat_label(label = c(all_categorical() ~ "n (%)", Age ~ "median (1st, 3rd quartiles)")) %>%
  modify_header(label = "", stat_by = "**{level} (N={n})**")

# Adults (>=15 years of age)
t3 <- dat %>%
  filter(age15=="Yes") %>%
  select(group2, Country, Age, Sex, Day, Serotype, Serology, Obesity, Diabetes, WHO2009, hospital) %>%
  tbl_summary(by = group2,
              statistic = list(all_continuous() ~ "{median} ({p25}, {p75})", all_categorical() ~ "{n} ({p})"),
              value = list(Sex ~ "Male"),
              digits = list(all_continuous() ~ c(0,0)),
              label = list(Age ~ "Age (years)", Sex ~ "Gender male", Day ~ "Illness day at enrolment",
                           Serology ~ "Immune status", WHO2009 ~ "WHO 2009 classification", hospital ~ "Hospitalization")) %>%
  add_stat_label(label = c(all_categorical() ~ "n (%)", Age ~ "median (1st, 3rd quartiles)")) %>%
  modify_header(label = "", stat_by = "**{level} (N={n})**")

# Merge tables
tbl_merge(tbls = list(t1, t2, t3),
          tab_spanner = c("**All patients**", "**Children**", "**Adults**")) %>%
  modify_footnote(update = label ~ "Obesity is defined as body mass index of higher than 30 kg/m2 (for patients of older than 18 years) or two standard deviations of the median of body mass index for age (for patients of 18 years or below). WHO: World Health Organization.")

Summary of clinical data by primary outcome.

Biomarker levels

On average, the patients who progressed to S/MD had higher levels of the biomarkers in both children and adult patients, both at enrollment and at follow-up (Figure 2, Appendix 4—table 2). For most individuals, the levels of five biomarkers (VCAM-1, IL-8, IP-10, IL-1RA, and CRP) decreased between enrollment and follow-up, whereas SDC-1 increased slightly and the other markers showed no clear trends (Appendix 4—figure 1). In some of the cases the biomarkers did not return to normal at convalescence. Moderate-to-strong positive correlations were evident for some markers, in particular IP-10 and IL-1RA, and IP-10 and VCAM-1, both with Spearman’s rank correlation coefficients above 0.6 (Appendix 4—figure 2).

Figure 2.

#' @width 28
#' @height 20

tick <- c(0,1,4,10,40,100,200,400,1000,4000,10000,20000,40000,70000) # for y-axis tick labels

dat_plot %>%
  ggplot(., aes(Daygr, Result^(1/4), fill=group2, color=group2)) +
  geom_boxplot(alpha=.5, outlier.size=.9, lwd=.4, fatten=1) +
  geom_boxplot(alpha=0, outlier.color=NA, color="black", lwd=.4, fatten=1) +
  facet_wrap(~ Biomarker, scales="free", ncol=5) +
  scale_y_continuous(breaks=tick^(1/4), labels=tick) +
  xlab("Illness day (day 1 [n=140]; day 2 [n=390]; day 3 [n=307]; day 10-20 [n=625]; day >20 [n=43])") +
  theme(axis.title.y=element_blank(), legend.position="top", legend.title=element_blank(),
        axis.text.y=element_text(size=rel(.8)))

Biomarker levels by groups.

VCAM-1: vascular cell adhesion molecule-1; SDC-1: syndecan-1; Ang-2: angiopoietin-2; IL-8: interleukin-8; IP-10: interferon gamma-induced protein-10; IL-1RA: interleukin-1 receptor antagonist; sCD163: soluble cluster of differentiation 163; sTREM-1: soluble triggering receptor expressed on myeloid cells-1; CRP: C-reactive protein. Y-axes are transformed using the fourth root transformation.

Associations between biomarker levels and the endpoints

In the single models, higher levels of each biomarker on illness days 1, 2, or 3 increased the risk of developing S/MD, with the exception of ferritin in adults where there was a downward trend at higher values (Figure 3, Table 2). We observed differences between children and adults for several biomarkers, the most pronounced being SDC-1, IL-8, ferritin, and IL-1RA. Associations between SDC-1 and IL-8 and the S/MD endpoint were stronger in adults than children, while the effects of IL-1RA and ferritin were stronger in children than adults.

Figure 3.

#' @width 28
#' @height 20

# Set datadist for 'lrm' function [rms]
dd <- datadist(dat1); options(datadist="dd")

# Get results from models for children
dd$limits["Adjust to","Age"] <- 10

dat_m1 <- get_pred1(out="sev.or.inte", bio="VCAM", age=10, dat=dat1) %>% rename(value=VCAM) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_m2 <- get_pred1(out="sev.or.inte", bio="SDC", age=10, dat=dat1) %>% rename(value=SDC) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_m3 <- get_pred1(out="sev.or.inte", bio="Ang", age=10, dat=dat1) %>% rename(value=Ang) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_m4 <- get_pred1(out="sev.or.inte", bio="IL8", age=10, dat=dat1) %>% rename(value=IL8) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_m5 <- get_pred1(out="sev.or.inte", bio="IP10", age=10, dat=dat1) %>% rename(value=IP10) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_m6 <- get_pred1(out="sev.or.inte", bio="IL1RA", age=10, dat=dat1) %>% rename(value=IL1RA) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_m7 <- get_pred1(out="sev.or.inte", bio="CD163", age=10, dat=dat1) %>% rename(value=CD163) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_m8 <- get_pred1(out="sev.or.inte", bio="TREM", age=10, dat=dat1) %>% rename(value=TREM) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_m9 <- get_pred1(out="sev.or.inte", bio="Fer", age=10, dat=dat1) %>% rename(value=Fer) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_m10 <- get_pred1(out="sev.or.inte", bio="CRP", age=10, dat=dat1) %>% rename(value=CRP) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))

dat_mg1 <- get_pred2(out="sev.or.inte", bio="VCAM", age=10, dat=dat1) %>% rename(value=VCAM) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_mg2 <- get_pred2(out="sev.or.inte", bio="SDC", age=10, dat=dat1) %>% rename(value=SDC) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_mg3 <- get_pred2(out="sev.or.inte", bio="Ang", age=10, dat=dat1) %>% rename(value=Ang) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_mg4 <- get_pred2(out="sev.or.inte", bio="IL8", age=10, dat=dat1) %>% rename(value=IL8) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_mg5 <- get_pred2(out="sev.or.inte", bio="IP10", age=10, dat=dat1) %>% rename(value=IP10) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_mg6 <- get_pred2(out="sev.or.inte", bio="IL1RA", age=10, dat=dat1) %>% rename(value=IL1RA) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_mg7 <- get_pred2(out="sev.or.inte", bio="CD163", age=10, dat=dat1) %>% rename(value=CD163) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_mg8 <- get_pred2(out="sev.or.inte", bio="TREM", age=10, dat=dat1) %>% rename(value=TREM) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_mg9 <- get_pred2(out="sev.or.inte", bio="Fer", age=10, dat=dat1) %>% rename(value=Fer) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))
dat_mg10 <- get_pred2(out="sev.or.inte", bio="CRP", age=10, dat=dat1) %>% rename(value=CRP) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="Under 15"))

dat_p1 <- rbind(dat_m1,dat_mg1, dat_m2,dat_mg2, dat_m3,dat_mg3, dat_m4,dat_mg4, dat_m5,dat_mg5, dat_m6,dat_mg6, dat_m7,dat_mg7, dat_m8,dat_mg8, dat_m9,dat_mg9, dat_m10,dat_mg10) %>%
  mutate(age = "10 years")

# Get results from models for adults
dd$limits["Adjust to","Age"] <- 25

dat_m1 <- get_pred1(out="sev.or.inte", bio="VCAM", age=25, dat=dat1) %>% rename(value=VCAM) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_m2 <- get_pred1(out="sev.or.inte", bio="SDC", age=25, dat=dat1) %>% rename(value=SDC) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_m3 <- get_pred1(out="sev.or.inte", bio="Ang", age=25, dat=dat1) %>% rename(value=Ang) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_m4 <- get_pred1(out="sev.or.inte", bio="IL8", age=25, dat=dat1) %>% rename(value=IL8) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_m5 <- get_pred1(out="sev.or.inte", bio="IP10", age=25, dat=dat1) %>% rename(value=IP10) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_m6 <- get_pred1(out="sev.or.inte", bio="IL1RA", age=25, dat=dat1) %>% rename(value=IL1RA) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_m7 <- get_pred1(out="sev.or.inte", bio="CD163", age=25, dat=dat1) %>% rename(value=CD163) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_m8 <- get_pred1(out="sev.or.inte", bio="TREM", age=25, dat=dat1) %>% rename(value=TREM) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_m9 <- get_pred1(out="sev.or.inte", bio="Fer", age=25, dat=dat1) %>% rename(value=Fer) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_m10 <- get_pred1(out="sev.or.inte", bio="CRP", age=25, dat=dat1) %>% rename(value=CRP) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))

dat_mg1 <- get_pred2(out="sev.or.inte", bio="VCAM", age=25, dat=dat1) %>% rename(value=VCAM) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_mg2 <- get_pred2(out="sev.or.inte", bio="SDC", age=25, dat=dat1) %>% rename(value=SDC) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_mg3 <- get_pred2(out="sev.or.inte", bio="Ang", age=25, dat=dat1) %>% rename(value=Ang) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_mg4 <- get_pred2(out="sev.or.inte", bio="IL8", age=25, dat=dat1) %>% rename(value=IL8) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_mg5 <- get_pred2(out="sev.or.inte", bio="IP10", age=25, dat=dat1) %>% rename(value=IP10) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_mg6 <- get_pred2(out="sev.or.inte", bio="IL1RA", age=25, dat=dat1) %>% rename(value=IL1RA) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_mg7 <- get_pred2(out="sev.or.inte", bio="CD163", age=25, dat=dat1) %>% rename(value=CD163) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_mg8 <- get_pred2(out="sev.or.inte", bio="TREM", age=25, dat=dat1) %>% rename(value=TREM) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_mg9 <- get_pred2(out="sev.or.inte", bio="Fer", age=25, dat=dat1) %>% rename(value=Fer) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))
dat_mg10 <- get_pred2(out="sev.or.inte", bio="CRP", age=25, dat=dat1) %>% rename(value=CRP) %>% 
  select(value, yhat, lower, upper, biomarker, model) %>% slice(which(dat1$age15=="15 and above"))

dat_p2 <- rbind(dat_m1,dat_mg1, dat_m2,dat_mg2, dat_m3,dat_mg3, dat_m4,dat_mg4, dat_m5,dat_mg5, dat_m6,dat_mg6, dat_m7,dat_mg7, dat_m8,dat_mg8, dat_m9,dat_mg9, dat_m10,dat_mg10) %>%
  mutate(age = "25 years")

# Merge results for children and adults
vis1 <- rbind(dat_p1, dat_p2) %>% mutate(outcome = "outcome 1")

# Merge data for plots
tmp0 <- dat1 %>% arrange(age15) %>% select(sev.or.inte)
tmp <- data.frame(sev.or.inte = rep(tmp0$sev.or.inte, 20))
  
tmp_p1 <- vis1 %>%
  arrange(biomarker, model) %>%
  mutate(value1 = 2^value,
         age = factor(age, levels=c("10 years", "25 years")),
         gr = ifelse(model=="Single model" & age=="10 years", 1,
                     ifelse(model=="Single model" & age=="25 years", 2,
                            ifelse(model=="Global model" & age=="10 years", 3, 4))),
         gr = factor(gr, levels=c(1:4), labels=c("Single children", "Single adults", "Global children", "Global adults")),
         model = factor(model, levels=c("Single model", "Global model"))) %>%
  bind_cols(., tmp)

vline <- tmp_p1 %>%
  filter(model=="Single model") %>%
  filter(yhat==0) %>%
  select(biomarker, value, value1) %>%
  rename(vline=value, vline1=value1)

dat_p <- left_join(tmp_p1, vline, by="biomarker")

# Alternative data to limit to 5th - 95th of the values
dat_alt <- dat_p %>%
  group_by(biomarker, model) %>%
  mutate(up = quantile(value, .95),
         lo = quantile(value, .05)) %>%
  ungroup() %>%
  mutate(is.outlier = value<lo | value>up | value<0,
         value = ifelse(is.outlier, NA, value),
         value1 = ifelse(is.outlier, NA, value1),
         yhat = ifelse(is.outlier, NA, yhat),
         lower = ifelse(is.outlier, NA, lower),
         upper = ifelse(is.outlier, NA, upper))

dat_1_5 <- dat_alt %>% 
  filter(biomarker %in% c("VCAM", "SDC", "Ang", "IL8", "IP10")) %>%
  mutate(biomarker = factor(biomarker, levels=c("VCAM", "SDC", "Ang", "IL8", "IP10")))

dat_6_10 <- dat_alt %>% 
  filter(biomarker %in% c("IL1RA", "CD163", "TREM", "Fer", "CRP")) %>%
  mutate(biomarker = factor(biomarker, levels=c("IL1RA", "CD163", "TREM", "Fer", "CRP")))

# Modify facets' scales
require(facetscales)
xVCAM <- c(1,4,15,60,250,1000,4000)
xSDC <- c(1400,2000,2800,4000,5600)
xAng <- c(50,100,250,500,1000,2000)
xIL8 <- c(5,7,10,14,20,28,40)
xIP10 <- c(25,100,400,1600,6400)
xIL1RA <- c(1000,2000,4000,8000,16000)
xCD163 <- c(75,150,300,600)
xTREM <- c(35,50,70,100,140,200)
xFer <- c(50,100,200,400,800)
xCRP <- c(2.5,5,10,20,40,80)

scales_x <- list(
  `VCAM` = scale_x_continuous(breaks = log2(xVCAM), labels = xVCAM),
  `SDC` = scale_x_continuous(breaks = log2(xSDC), labels = xSDC),
  `Ang` = scale_x_continuous(breaks = log2(xAng), labels = xAng), 
  `IL8` = scale_x_continuous(breaks = log2(xIL8), labels = xIL8), 
  `IP10` = scale_x_continuous(breaks = log2(xIP10), labels = xIP10), 
  `IL1RA` = scale_x_continuous(breaks = log2(xIL1RA), labels = xIL1RA), 
  `CD163` = scale_x_continuous(breaks = log2(xCD163), labels = xCD163), 
  `TREM` = scale_x_continuous(breaks = log2(xTREM), labels = xTREM), 
  `Fer` = scale_x_continuous(breaks = log2(xFer), labels = xFer), 
  `CRP` = scale_x_continuous(breaks = log2(xCRP), labels = xCRP)
)

ybreak1 <- c(.125, .25, .5, 1, 2, 4, 8)
ybreak2 <- c(.125, .25, .5, 1, 2, 4)

scales_y1 <- list(
  `Single model` = scale_y_continuous(limits = c(log(.124), log(8.01)), breaks = log(ybreak1), labels = ybreak1),
  `Global model` = scale_y_continuous(limits = c(log(.124), log(8.01)), breaks = log(ybreak1), labels = ybreak1)
)

scales_y2 <- list(
  `Single model` = scale_y_continuous(limits = c(log(.124), log(4.01)), breaks = log(ybreak2), labels = ybreak2),
  `Global model` = scale_y_continuous(limits = c(log(.124), log(4.01)), breaks = log(ybreak2), labels = ybreak2)
)

# Set facets' names
models <- c(`Single model` = "Single model",
            `Global model` = "Global model")

biomarkers <- c(`VCAM` = "VCAM-1 (ng/ml)",
                `SDC`= "SDC-1 (pg/ml)",
                `Ang` = "Ang-2 (pg/ml)",
                `IL8` = "IL-8 (pg/ml)",
                `IP10` = "IP-10 (pg/ml)",
                `IL1RA` = "IL-1RA (pg/ml)",
                `CD163` = "sCD163 (ng/ml)",
                `TREM` = "sTREM-1 (pg/ml)",
                `Fer` = "Ferritin (ng/ml)",
                `CRP` = "CRP (mg/l)")

# Plot for the first 5 biomarkers
p.1.5 <- ggplot(dat_1_5, aes(x=value)) +
  geom_ribbon(aes(ymin=lower, ymax=upper, fill=age), alpha=.15) +
  geom_vline(aes(xintercept=vline), color="black", linetype="dashed", alpha=.4) +
  geom_hline(yintercept=0, color="black", linetype="dashed", alpha=.4) +
  geom_line(aes(y=yhat, color=age), size=.5, alpha=.7) +
  geom_rug(data=filter(dat_1_5, model=="Single model" & sev.or.inte==0 & age=="10 years"), sides="b", alpha=.2, color="red") +
  geom_rug(data=filter(dat_1_5, model=="Single model" & sev.or.inte==1 & age=="10 years"), sides="t", alpha=.2, color="red") +
  geom_rug(data=filter(dat_1_5, model=="Global model" & sev.or.inte==0 & age=="25 years"), sides="b", alpha=.2, color="blue") +
  geom_rug(data=filter(dat_1_5, model=="Global model" & sev.or.inte==1 & age=="25 years"), sides="t", alpha=.2, color="blue") +
  scale_color_manual(values=c("red","blue"), labels=c("Children","Adults")) +
  scale_fill_manual(values=c("red","blue"), labels=c("Children","Adults")) +
  ylab("Odds ratio") +
  theme(legend.position="top", legend.title=element_blank(), axis.title.x=element_blank(), axis.text.x=element_text(angle=45)) +
  facet_grid_sc(cols=vars(biomarker), rows=vars(model), 
                scales=list(x=scales_x, y=scales_y1),
                labeller = as_labeller(c(models, biomarkers)))

# Plot for the last 5 biomarkers
p.6.10 <- ggplot(dat_6_10, aes(x=value)) +
  geom_ribbon(aes(ymin=lower, ymax=upper, fill=age), alpha=.15) +
  geom_vline(aes(xintercept=vline), color="black", linetype="dashed", alpha=.4) +
  geom_hline(yintercept=0, color="black", linetype="dashed", alpha=.4) +
  geom_line(aes(y=yhat, color=age), size=.5, alpha=.7) +
  geom_rug(data=filter(dat_6_10, model=="Single model" & sev.or.inte==0 & age=="10 years"), sides="b", alpha=.2, color="red") +
  geom_rug(data=filter(dat_6_10, model=="Single model" & sev.or.inte==1 & age=="10 years"), sides="t", alpha=.2, color="red") +
  geom_rug(data=filter(dat_6_10, model=="Global model" & sev.or.inte==0 & age=="25 years"), sides="b", alpha=.2, color="blue") +
  geom_rug(data=filter(dat_6_10, model=="Global model" & sev.or.inte==1 & age=="25 years"), sides="t", alpha=.2, color="blue") +
  scale_color_manual(values=c("red","blue"), labels=c("Children","Adults")) +
  scale_fill_manual(values=c("red","blue"), labels=c("Children","Adults")) +
  ylab("Odds ratio") +
  theme(legend.position="none", axis.title.x=element_blank(), axis.text.x=element_text(angle=45)) +
  facet_grid_sc(cols=vars(biomarker), rows=vars(model), 
                scales=list(x=scales_x, y=scales_y2),
                labeller = as_labeller(c(models, biomarkers)))

# Merge plots
gridExtra::grid.arrange(p.1.5, p.6.10, nrow=2, heights=c(1,.86))

Results from models for the primary endpoint (severe or moderate dengue).

The odds ratio of severe/moderate dengue (the red and blue lines) and 95% confidence interval (the red and blue regions) are estimated from multivariable logistic regression models allowing for a non-linear relation of log-2 of the biomarker level with severe/moderate dengue using restricted cubic splines. Each single model contains the corresponding biomarker, age and their interaction, while the global model contains all biomarkers and their interaction with age. The reference values for the odds ratios (where the odds ratio is equal to 1) are represented by the vertical gray dashed lines. They are chosen as the median of the biomarker levels of the whole study population (VCAM-1: 1636 ng/ml; SDC-1: 2519 pg/ml; Ang-2: 1204 pg/ml; IL-8: 14 pg/ml; IP-10: 3093 pg/ml; IL-1RA: 6434 pg/ml; sCD163: 295 ng/ml; sTREM-1: 85 ng/ml; ferritin: 243 ng/ml; and CRP: 28 mg/l). The x-axis represents biomarker levels; it is transformed using log-2 and its range truncated by the 5th and 95th percentiles of the biomarker levels of the whole study population. The rug plot on the x-axis represents the distribution of individual cases; the bottom rug plot represents the uncomplicated dengue cases and the top rug plot represents the severe/moderate dengue cases (children [<15 years of age] are in red and adults [≥15 years of age] are in blue). The red line and region represent children; results are shown for children at age of 10 years. The blue line and region represents adults; results are shown for adults at age of 25 years. VCAM-1: vascular cell adhesion molecule-1; SDC-1: syndecan-1; Ang-2: angiopoietin-2; IL-8: interleukin-8; IP-10: interferon gamma-induced protein-10; IL-1RA: interleukin-1 receptor antagonist; sCD163: soluble cluster of differentiation 163; sTREM-1: soluble triggering receptor expressed on myeloid cells-1; CRP: C-reactive protein.

Table 2.

# Set datadist for 'lrm' function [rms]
dd <- datadist(dat1); options(datadist="dd")

# Use my function 'get_est1' to get ORs and CIs from models
tmp1 <- data.frame(
  sort1 = rep(c(1:10), 2),
  sort2 = c(rep(2,10), rep(3,10)),
  bio = rep(c("VCAM", "SDC", "Ang", "IL8", "IP10", "IL1RA", "CD163", "TREM", "Fer", "CRP"), 2),
  ref1 = c(ref0-1, ref0),
  ref2 = c(ref0, ref0+1)
) %>%
  arrange(sort1, sort2) %>%
  group_by(sort1, sort2) %>%
  do(cbind(.,
           # Children - single models
           or1c = get_est1(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="OR", age=10, dat=dat1),
           lo1c = get_est1(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="loCI", age=10, dat=dat1),
           up1c = get_est1(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="upCI", age=10, dat=dat1),
           # Children - global model
           or2c = get_est2(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="OR", age=10, dat=dat1),
           lo2c = get_est2(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="loCI", age=10, dat=dat1),
           up2c = get_est2(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="upCI", age=10, dat=dat1),
           # Adults - single models
           or1a = get_est1(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="OR", age=25, dat=dat1),
           lo1a = get_est1(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="loCI", age=25, dat=dat1),
           up1a = get_est1(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="upCI", age=25, dat=dat1),
           # Adults - global model
           or2a = get_est2(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="OR", age=25, dat=dat1),
           lo2a = get_est2(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="loCI", age=25, dat=dat1),
           up2a = get_est2(out="sev.or.inte", bio=.$bio, ref1=.$ref1, ref2=.$ref2, est="upCI", age=25, dat=dat1))) %>%
  ungroup()
for (i in 6:17) {tmp1[[i]] <- sprintf("%.2f", round(tmp1[[i]],2))}

# Use my function 'get_est1' to get p-values from models
tmp2 <- data.frame(
  sort1 = c(1:10),
  sort2 = rep(1,10),
  bio = c("VCAM", "SDC", "Ang", "IL8", "IP10", "IL1RA", "CD163", "TREM", "Fer", "CRP")
) %>%
  group_by(sort1) %>%
  do(cbind(.,
           p.s1 = get_est1(out="sev.or.inte", bio=.$bio, est="p", dat=dat1), # P overall from single models
           p.s1_int = get_est1(out="sev.or.inte", bio=.$bio, est="p int", dat=dat1), # P interaction from single models
           p.g1 = get_est2(out="sev.or.inte", bio=.$bio, est="p", dat=dat1), # P overall from global models
           p.g1_int = get_est2(out="sev.or.inte", bio=.$bio, est="p int", dat=dat1))) %>% # P interaction from global models
  ungroup()
for (i in 4:7) {tmp2[[i]] <- ifelse(tmp2[[i]]<0.001, "<0.001", sprintf("%.3f", round(tmp2[[i]],3)))}  

# Combine results into a table
res1 <- bind_rows(tmp1, tmp2) %>%
  arrange(sort1, sort2) %>%
  mutate(bio = ifelse(!is.na(ref1), paste(" -", round(2^ref2,0), "vs", round(2^ref1,0), sep=" "), as.character(bio)),
         or.sc1 = ifelse(is.na(lo1c), NA, paste(or1c, " (", lo1c, "-", up1c, ")", sep="")), # s: single model; c: children
         or.gc1 = ifelse(is.na(lo2c), NA, paste(or2c, " (", lo2c, "-", up2c, ")", sep="")), # g: global model
         or.sa1 = ifelse(is.na(lo1a), NA, paste(or1a, " (", lo1a, "-", up1a, ")", sep="")), # a: adults
         or.ga1 = ifelse(is.na(lo2a), NA, paste(or2a, " (", lo2a, "-", up2a, ")", sep=""))) %>%
  select(bio, or.sc1, or.sa1, p.s1, p.s1_int, or.gc1, or.ga1, p.g1, p.g1_int)

names(res1) <- c("", "OR (children - single)", "OR (adults - single)", "P overall (single)", "P interaction (single)",
                 "OR (children - global)", "OR (adults - global)", "P overall (global)", "P interaction (global)")

# Report the results
res1

Results from models for the primary endpoint (severe or moderate dengue).

P_overall is derived from Wald test for the overall association of the biomarker with the endpoint; P_interaction is from the test for the interaction between the biomarker and age. The odds ratios are estimated at age of 10 and 25 years, represented as children and adults respectively.

In the global model there were some differences compared to the single models (Figure 3, Table 2). The biomarkers SDC-1 and IL-1RA were the most stable relative to the single models for both children and adults. However, for IP-10 the trend of the association with S/MD changed from positive to negative in both children and adults. In children, VCAM-1 changed the trend from positive to weakly negative and IL-8 changed the trend from weakly positive to negative. Other biomarkers showed weaker associations with the endpoint in the global model based on the ORs. In addition, the differences of the associations between children and adults were more marked, particularly for Ang-2, IL-8, and ferritin.

The sensitivity analysis showed that the association between the biomarkers and S/MD did not differ between DENV-1 and other serotypes (Appendix 5—figure 1; Appendix 5—figure 2; Appendix 5—table 1; Appendix 5—table 2). Similar patterns were observed in the various analyses related to the secondary endpoints, as described in detail in the Appendix 6 (Appendix 6—figure 1; Appendix 6—figure 2, Appendix 6—table 1; Appendix 6—table 2, Appendix 6—table 3).

Best combinations of biomarkers associated with the primary endpoint

For children, the best subset that showed the clearest association with S/MD was the combination of the six markers IL-1RA, Ang-2, IL-8, ferritin, IP-10, and SDC-1 with an AIC of 465.9. This model was selected most often in the bootstrap procedure, but was not highly robust (it was selected in 134 of the 1000 samples) (Table 3, Appendix 7—table 1). Over the 1000 samples, the six variables had an inclusion frequency ranging from 73.5% for SDC-1 to 100% for IL-1RA. The most important biomarkers in order were IL-1RA, Ang-2, IL-8, and ferritin (Appendix 7—table 2). The best combination of two biomarkers was IL-1RA and ferritin, the best of three added Ang-2, the best of four added IP-10, and the best of five added IL-8. The best combinations of two and five variables were most robust with a selection percentage of 43.7% and 44%. The best of five had almost the same AIC as the best subset of six markers (467.6 versus 465.9) (Table 3). The coefficients of the selected biomarkers were similar to the initial model estimates (Appendix 7—table 2).

Table 3.

# EPV --------------------------------------------------------------
pred <- c("VCAM", "SDC", "Ang", "IL8", "IP10", "IL1RA", "CD163", "TREM", "Fer", "CRP")

# Estimate full model ----------------------------------------------
full_mod <- glm(sev.or.inte ~ VCAM + SDC + Ang + IL8 + IP10 + IL1RA + CD163 + TREM + Fer + CRP, 
                family=binomial, data=dat1c, x=T, y=T)

# Selected model ---------------------------------------------------
sel_var <- matrix(0, ncol=length(pred)+1, nrow=5, dimnames=list(NULL, c(pred, "aic")))

for (i in 1:5) {
  if (i==1) {
    bs <- dredge(full_mod, rank="AIC")
  } else {
    bs <- dredge(full_mod, rank="AIC", m.lim=c(i,i))
  }
  bs_var <- attr(get.models(bs, 1)[[1]]$terms, "term.labels")

  for (j in 1:(ncol(sel_var)-1)) {sel_var[i,j] <- ifelse(names(sel_var[i,j]) %in% bs_var, 1, 0)}
  formula <- paste("sev.or.inte~", paste(names(sel_var[i,][sel_var[i,]==1]), collapse = "+"))
  sel_mod <- glm(formula, data = dat1c, family = binomial, x = T, y = T)
  sel_var[i, ncol(sel_var)] <- AIC(sel_mod)
}

# Report results --------------------------------------------------
out1 <- as.data.frame(sel_var) %>% mutate(AIC = round(aic,1)) %>% select(-aic)
for (i in 1:(ncol(out1)-1)) {out1[,i] <- ifelse(out1[,i]==0, NA, "+")}

out2 <- as.data.frame(t(out1))
colnames(out2) <- c("Best of all combinations", "Best combination of 2 variables", "Best combination of 3 variables",
                    "Best combination of 4 variables", "Best combination of 5 variables")
rownames(out2) <- c("- VCAM-1", "- SDC-1", "- Ang-2", "- IL-8", "- IP-10", "- IL-1RA", "- sCD163", "- sTREM-1",
                    "- Ferritin", "- CRP", "AIC of the selected model")

out2

# For bootstrap results please look at Appendix 7-tables 1, 2 (for the best of all combinations)
# and the bootstrap codes for the best combinations of 2, 3, 4, and 5 variables

Best combinations of biomarkers associated with severe or moderate dengue for children.

VCAM-1: vascular cell adhesion molecule-1; SDC-1: syndecan-1; Ang-2: angiopoietin-2; IL-8: interleukin-8; IP-10: interferon gamma-induced protein-10; IL- 1RA: interleukin-1 receptor antagonist; sCD163: soluble cluster of differentiation 163; sTREM-1: soluble triggering receptor expressed on myeloid cells-1; CRP: C-reactive protein; AIC: Akaike information criterion.

For adults, the best subset included the seven markers SDC-1, IL-8, ferritin, sTREM-1, IL-1RA, IP-10, and sCD163. This model was selected 79 times among 1000 bootstrap samples, but still was selected more often than the other models (Table 4, Appendix 7—table 3). Over the 1000 samples, the seven variables had a bootstrap inclusion frequency ranging from 59.1% for sCD163 to 99.2% for SDC-1. The three most important biomarkers in order were SDC-1, IL-8, and ferritin (Appendix 7—table 4). The best combination of two biomarkers included SDC-1 and IL-8, the best of three added ferritin, the best of four added IL-1RA, and the best of five added sTREM-1. The best combination of two was the most robust with a selection percentage of 56.7%, followed by the best of three variables (43.2%) (Table 4). The coefficients of the selected markers were also similar to the initial model estimates (Appendix 7—table 4).

Table 4.

# EPV --------------------------------------------------------------
pred <- c("VCAM", "SDC", "Ang", "IL8", "ns1(IP10)", "IL1RA", "CD163", "TREM", "Fer", "CRP")

# Estimate full model ----------------------------------------------
full_mod <- glm(sev.or.inte ~ VCAM + SDC + Ang + IL8 + ns1(IP10) + IL1RA + CD163 + TREM + Fer + CRP, 
                family=binomial, data=dat1a, x=T, y=T)

# Selected model ---------------------------------------------------
sel_var <- matrix(0, ncol=length(pred)+1, nrow=5, dimnames=list(NULL, c(pred, "aic")))

for (i in 1:5) {
  if (i==1) {
    bs <- dredge(full_mod, rank="AIC")
  } else {
    bs <- dredge(full_mod, rank="AIC", m.lim=c(i,i))
  }
  bs_var <- attr(get.models(bs, 1)[[1]]$terms, "term.labels")

  for (j in 1:(ncol(sel_var)-1)) {sel_var[i,j] <- ifelse(names(sel_var[i,j]) %in% bs_var, 1, 0)}
  formula <- paste("sev.or.inte~", paste(names(sel_var[i,][sel_var[i,]==1]), collapse = "+"))
  sel_mod <- glm(formula, data = dat1a, family = binomial, x = T, y = T)
  sel_var[i, ncol(sel_var)] <- AIC(sel_mod)
}

# Report results --------------------------------------------------
out1 <- as.data.frame(sel_var) %>% mutate(AIC = round(aic,1)) %>% select(-aic)
for (i in 1:(ncol(out1)-1)) {out1[,i] <- ifelse(out1[,i]==0, NA, "+")}

out2 <- as.data.frame(t(out1))
colnames(out2) <- c("Best of all combinations", "Best combination of 2 variables", "Best combination of 3 variables",
                    "Best combination of 4 variables", "Best combination of 5 variables")
rownames(out2) <- c("- VCAM-1", "- SDC-1", "- Ang-2", "- IL-8", "- IP-10", "- IL-1RA", "- sCD163", "- sTREM-1",
                    "- Ferritin", "- CRP", "AIC of the selected model")

out2

# For bootstrap results please look at Appendix 7-tables 3, 4 (for the best of all combinations)
# and the bootstrap codes for the best combinations of 2, 3, 4, and 5 variables

Best combinations of biomarkers associated with severe or moderate dengue for adults.

VCAM-1: vascular cell adhesion molecule-1; SDC-1: syndecan-1; Ang-2: angiopoietin-2; IL-8: interleukin-8; IP-10: interferon gamma-induced protein-10; IL- 1RA: interleukin-1 receptor antagonist; sCD163: soluble cluster of differentiation 163; sTREM-1: soluble triggering receptor expressed on myeloid cells-1; CRP: C-reactive protein; AIC: Akaike information criterion. *Variable is kept as non-linear effect using natural cubic splines with three knots.

In the sensitivity analysis, viremia was not selected in any of the best combinations for children, and the marker combinations remained the same as the main analysis. For adults, the best subset included five markers SDC-1, IL-8, ferritin, viremia and sCD163. The best of two and three were the same as the main analysis; viremia was selected in the best of four and five (Appendix 8—figure 1; Appendix 8—table 1; Appendix 8—table 2; Appendix 8—table 3).

Discussion

This nested case-control study has shown that a range of endothelial, immune activation and inflammatory biomarkers measured during the early febrile phase of dengue are associated with progression to worse clinical outcomes in both children and adults. In children we found IL-1RA to have the most robust association with S/MD, whereas in adults we found SDC-1 and IL-8 to have the most robust association. For children, the best combination (ordered by robustness) included six biomarkers IL-1RA, Ang-2, IL-8, ferritin, IP-10, and SDC-1; for adults the best combination identified comprised seven biomarkers SDC-1, IL-8, ferritin, sTREM-1, IL-1RA, IP-10, and sCD163.

Our results add to the current literature on biomarkers in severe/moderate dengue compared with uncomplicated dengue, by including early time-points prior to the development of the severe manifestations, as well as providing data on the use of biomarker combinations, which takes into consideration the complex inflammatory-vascular pathogenesis of severe dengue. We observed that there were marked changes in the associations between individual biomarkers and outcomes when considering them together, while other biomarkers showed consistent associations. Particularly, the association of IP-10 with S/MD changed significantly from the single to global model, which may be because another biomarker in our model is a mediator or confounder of IP-10 in the pathway to the outcome. This could be IL-1RA as its association with S/MD was similar between the single and global model, and the correlation between IP-10 and IL-1RA was strong (Spearman’s rank correlation coefficient was 0.75). Nonetheless, changing the direction of the association from the single to global model does not diminish the possibility of that biomarker being selected in the best combinations.

Our study also demonstrates some key differences between pediatric and adult dengue. Clinical phenotypes of dengue in children and adults differ, with children experiencing more shock and adults more organ impairment and bleeding, with distinct clinical management guidelines published by the WHO. Our results imply dengue pathogenesis may differ by age, with distinct combinations of immune-activation and vascular markers demonstrated between children and adults. Specifically, the association of IL-8 and ferritin differed between children and adults, which is likely to be due to the composite endpoint of severe and moderate dengue. As shown in the analysis of severe dengue alone (Appendix 4—figure 1, Appendix 4—table 1), the effects of IL-8 and ferritin were similar in children and adults, which suggests these biomarkers are still associated with severe disease in all age groups and that the difference is driven by the moderate dengue group. In addition, uncomplicated dengue in adults have higher ferritin levels compared to in children, with increasing age and chronic conditions in adults likely contributing to this observation. Hence patients’ age should be considered when developing biomarker panels for dengue risk prediction.

The use of biomarker panels for the prediction of severe outcomes in dengue has been investigated in previous studies, using several statistical approaches 3Brasier et al.20125Conroy et al.201514Ju and Brasier201316Lee et al.201625Pang et al.2016. However, because of small sample size and differences in the biomarkers assessed, the associations found vary between studies and as yet there are no validated prognostic panels for dengue. Dengue cases are forecasted to increase over the next few decades and, given the limited healthcare resources available in many endemic settings, particularly during epidemics, there is an urgent need to develop innovative methods to rapidly identify patients likely to develop complications and require hospital care 33Rodriguez-Manzano et al.2018. Previously, we showed that CRP as a single biomarker was useful for early dengue diagnosis and risk identification, which is currently easy to use in all settings 45Vuong et al.2020. Recently, we also showed that higher plasma viremia was associated with increased dengue severity regardless of age, serotype and immune status of patients 46Vuong et al.2021. However, future point-of-care testing could be improved by using a combination of biomarkers outlined in this study. Our results are applicable to the development of point-of-care panels capable of multiplex analysis and suited for use in outpatient settings for dengue prognosis, with scope for incorporation with innovative point-of-care technologies. To be more applicable by balancing model fit, robustness, and parsimony, we suggest the combination of five biomarkers IL-1RA, Ang-2, IL-8, ferritin, and IP-10 for children, and the combination of three biomarkers SDC-1, IL-8, and ferritin for adults to be used in practice. These combinations had a similar AIC with the best combinations (the difference of AIC was less than 5), but they required fewer number of biomarkers in a test panel. With the advent of novel technologies including microarray platforms and multiplex lateral flow assays, the cost is likely to come down in the future, allowing for wide-spread use in low-to-middle-income countries.

Methods of variable selection have been discussed previously but there remains no clear consensus regarding the best approach 10Heinze et al.201835Sauerbrei et al.2020. We adopted a data-driven ‘best subset’ approach which we think offers advantages over other methods, given the complexity of the biomarkers involved and their interactions. We also explored other approaches for variable selection 10Heinze et al.201826Piironen and Vehtari201735Sauerbrei et al.2020 and the results were very similar to the best subset procedure (Appendix 9—table 1; Appendix 9—table 2).

Strengths of our study include the large sample size and use of a nested case-control dataset from a prospective multi-country cohort study with consistent data collection and standardized outcome definitions and laboratory methodologies. The biomarker panel we selected was guided by pathogenesis studies, focusing on pathways activated early in the disease course, thus ensuring clinical relevance.

There are some limitations in our study. One being we analysed the biomarkers at only one time-point in the early phase; limited financial resources did not allow us to evaluate the full range of biomarkers across the whole IDAMS population and at more time-points. Secondly, this study was not designed to build prediction models so we did not use a measure of predictive value as a criterion, which was motivated by the nested case-control design. Our findings need to be validated in new studies.

In conclusion, higher levels of the ten biomarkers (VCAM-1, SDC-1, Ang-2, IL-8, IP-10, IL-1RA, sCD163, sTREM-1, ferritin, and CRP), when considered individually, are associated with increased risk of adverse clinical outcomes in both children and adults with dengue. The best biomarker combination for children includes IL-1RA, Ang-2, IL-8, ferritin, IP-10, and SDC-1; for adults, SDC-1, IL-8, ferritin, sTREM-1, IL-1RA, IP-10, and sCD163 were selected. These findings serve to assist the development of biomarker panels to improve future triage and early assessment of dengue patients. This would aid not only individual patient management and facilitate healthcare allocation which would be of major public health benefit especially in outbreak settings, but could also serve as potential biological endpoints for dengue clinical trials.

References

1. HAAb-Rahman
2. HRahim
3. SAbuBakar
4. PFWong
2016Macrophage activation Syndrome-Associated markers in severe dengue13International Journal of Medical Sciences179186
1. KBartoń
2020MuMIn: Multi-Model Inferencehttps://CRAN.R-project.org/package=MuMIn
1. ARBrasier
2. HJu
3. JGarcia
4. HMSpratt
5. SSVictor
6. BMForshey
7. ESHalsey
8. GComach
9. GSierra
10. PJBlair
11. CRocha
12. ACMorrison
13. TWScott
14. IBazan
15. TJKochel
16. Venezuelan Dengue Fever Working Group
2012A three-component biomarker panel for prediction of dengue hemorrhagic fever86The American Journal of Tropical Medicine and Hygiene341348
1. LCattarino
2. IRodriguez-Barraquer
3. NImai
4. DATCummings
5. NMFerguson
2020Mapping global variation in dengue transmission intensity12Science Translational Medicine
1. ALConroy
2. MGélvez
3. MHawkes
4. NRajwans
5. VTran
6. WCLiles
7. LAVillar-Centeno
8. KCKain
2015Host biomarkers are associated with progression to dengue haemorrhagic fever: a nested case-control study40International Journal of Infectious Diseases4553
1. JLFinkelstein
2. SColt
3. AJLayden
4. JTKrisher
5. AMStewart-Ibarra
6. MPolhemus
7. EBeltrán-Ayala
8. JMTedesco
9. WBCárdenas
10. TEndy
11. SMehta
2020Micronutrients, immunological parameters, and dengue virus infection in coastal Ecuador: a nested Case-Control study in an infectious disease surveillance program221The Journal of Infectious Diseases91101
1. LHan
2. XAo
3. SLin
4. SGuan
5. LZheng
6. XHan
7. HYe
2019Quantitative comparative proteomics reveal biomarkers for dengue disease severity10Frontiers in Microbiology
1. FEHarrell Jr
2019rms: Regression Modeling Strategieshttps://CRAN.R-project.org/package=rms
1. THastie
2. RTibshirani
3. RJTibshirani
2017Extended comparisons of best subset selection, forward stepwise selection, and the lassoarXivhttps://arxiv.org/abs/1707.08692
1. GHeinze
2. CWallisch
3. DDunkler
2018Variable selection - A review and recommendations for the practicing statistician60Biometrical Journal431449
1. RRHocking
2. RNLeslie
1967Selection of the best subset in regression analysis9Technometrics531540
1. TJaenisch
2. DTTam
3. NTKieu
4. TVan Ngoc
5. NTNam
6. NVan Kinh
7. SYacoub
8. NChanpheaktra
9. VKumar
10. LLSee
11. JSathar
12. EPSandoval
13. GMAlfaro
14. ISLaksono
15. YMahendradhata
16. MSarker
17. FAhmed
18. ACaprara
19. BSBenevides
20. ETMarques
21. TMagalhaes
22. PBrasil
23. MNetto
24. ATami
25. SEBethencourt
26. MGuzman
27. CSimmons
28. NTQuyen
29. LMerson
30. NTDung
31. DBeck
32. MWirths
33. MWolbers
34. PKLam
35. KRosenberger
36. BWills
2016Clinical evaluation of dengue and identification of risk factors for severe disease: protocol for a multicentre study in 8 countries16BMC Infectious Diseases
1. DVJohn
2. YSLin
3. GCPerng
2015Biomarkers of severe dengue disease - a review22Journal of Biomedical Science
1. HJu
2. ARBrasier
2013Variable selection methods for developing a biomarker panel for prediction of dengue hemorrhagic fever6BMC Research Notes
1. LCKatzelnick
2. LGresh
3. MEHalloran
4. JCMercado
5. GKuan
6. AGordon
7. ABalmaseda
8. EHarris
2017Antibody-dependent enhancement of severe dengue disease in humans358Science929932
1. YHLee
2. WYLeong
3. AWilder-Smith
2016Markers of dengue severity: a systematic review of cytokines and chemokines97Journal of General Virology31033119
1. MMapalagamage
2. SMHandunnetti
3. ARWickremasinghe
4. GPremawansa
5. SThillainathan
6. TFernando
7. KKanapathippillai
8. ADDe Silva
9. SPremawansa
2020High levels of serum angiopoietin 2 and angiopoietin 2/1 ratio at the critical stage of dengue hemorrhagic fever in patients and association with clinical and biochemical parameters58Journal of Clinical Microbiology
1. AMcBride
2. PKhanh Lam
2020Visual and biochemical evidence of glycocalyx disruption in human dengue infection, and association with plasma leakage severity7Frontiers of Medicine
1. CMMidgley
2. MBajwa-Joseph
3. SVasanawathana
4. WLimpitikul
5. BWills
6. AFlanagan
7. EWaiyaiya
8. HBTran
9. AECowper
10. PChotiyarnwong
11. PChotiyarnwon
12. JMGrimes
13. SYoksan
14. PMalasit
15. CPSimmons
16. JMongkolsapaya
17. GRScreaton
2011An in-depth analysis of original antigenic sin in dengue virus infection85Journal of Virology410421
1. NModhiran
2. DWatterson
3. DAMuller
4. AKPanetta
5. DPSester
6. LLiu
7. DAHume
8. KJStacey
9. PRYoung
2015Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity7Science Translational Medicine
1. MEMorra
2. AMAAltibi
3. SIqtadar
4. LHNMinh
5. SSElawady
6. AHallab
7. AElshafay
8. OAOmer
9. AIraqi
10. PAdhikari
11. JHLabib
12. KMElhusseiny
13. AElgebaly
14. SYacoub
15. LTMHuong
16. KHirayama
17. NTHuy
2018Definitions for warning signs and signs of severe dengue according to the WHO 2009 classification: systematic review of literature28Reviews in Medical Virology
1. SMukherjee
2. ATripathi
2020Association of serum C-reactive protein level and polymorphisms with susceptibility to dengue infection and severe clinical outcome among eastern indian patients209Medical Microbiology and Immunology631640
1. ROliveira
2. MTCordeiro
3. PMoura
4. PNBBaptista Filho
5. UMBraga-Neto
6. ETAMarques
7. LGil
2017Serum cytokine/chemokine profiles in patients with dengue fever (DF) and dengue hemorrhagic fever (FHD) by using protein array89Journal of Clinical Virology3945
1. NPandey
2. AJain
3. RKGarg
4. RKumar
5. OPAgrawal
6. PVLakshmana Rao
2015Serum levels of IL-8, IFNγ, IL-10, and TGF β and their gene expression levels in severe and non-severe cases of dengue virus infection160Archives of Virology14631475
1. JPang
2. ALindblom
3. TTolfvenstam
4. TLThein
5. ANNaim
6. LLing
7. AChow
8. MIChen
9. EEOoi
10. YSLeo
11. MLHibberd
2016Discovery and validation of prognostic biomarker models to guide triage among adult dengue patients at early infection11PLOS ONE
1. JPiironen
2. AVehtari
2017Comparison of bayesian predictive methods for model selection27Statistics and Computing711735
1. HPuerta-Guardo
2. DRGlasner
3. DAEspinosa
4. SBBiering
5. MPatana
6. KRatnasiri
7. CWang
8. PRBeatty
9. EHarris
2019Flavivirus NS1 triggers Tissue-Specific vascular endothelial dysfunction reflecting disease tropism26Cell Reports15981613
1. R Core Development Team
2020A language and environment for statistical computingR Foundation for Statistical Computing
1. ARathakrishnan
2. SMWang
3. YHu
4. AMKhan
5. SPonnampalavanar
6. LCLum
7. RManikam
8. SDSekaran
2012Cytokine expression profile of dengue patients at different phases of illness7PLOS ONE
1. APRathore
2. FSFarouk
3. ALSt John
2020Risk factors and biomarkers of severe dengue43Current Opinion in Virology18
1. MRedoni
2. SYacoub
3. LRivino
4. DRGiacobbe
5. RLuzzati
6. SDi Bella
2020Dengue: Status of current and under-development vaccines30Reviews in Medical Virology
1. MRobinson
2. SEinav
2020Towards Predicting Progression to Severe Dengue28Trends in Microbiology478486
1. JRodriguez-Manzano
2. PYChia
3. TWYeo
4. AHolmes
5. PGeorgiou
6. SYacoub
2018Improving Dengue Diagnostics and Management Through Innovative Technology20Current Infectious Disease Reports
1. SGS S
2. ABPillai
3. VSRamachandrappa
4. TKadhiravan
5. RDhodapkar
6. JKah
7. SRajendiran
2017Increased serum levels of macrophage activation marker sCD163 in dengue patients86Journal of Clinical Virology : The Official Publication of the Pan American Society for Clinical Virology6267
1. WSauerbrei
2. APerperoglou
3. MSchmid
4. MAbrahamowicz
5. HBecher
6. HBinder
7. DDunkler
8. FEHarrell
9. PRoyston
10. GHeinze
11. for TG2 of the STRATOS initiative
2020State of the art in selection of variables and functional forms in multivariable analysis-outstanding issues4Diagnostic and Prognostic Research
1. EDSchifano
2019A review of analysis methods for secondary outcomes in case-control studies26Communications for Statistical Applications and Methods103129
1. GScreaton
2. JMongkolsapaya
3. SYacoub
4. CRoberts
2015New insights into the immunopathology and control of dengue virus infection15Nature Reviews Immunology745759
1. KMSoo
2. BKhalid
3. SMChing
4. CLTham
5. RBasir
6. HYChee
2017Meta-analysis of biomarkers for severe dengue infections5PeerJ
1. RSoundravally
2. BAgieshkumar
3. MDaisy
4. JSherin
5. CCCleetus
2015Ferritin levels predict severe dengue43Infection1319
1. ALSt John
2. APRathore
3. BRaghavan
4. MLNg
5. SNAbraham
2013Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage2eLife
1. SSuwarto
2. RTSasmono
3. RSinto
4. EIbrahim
5. MSuryamin
2017Association of endothelial glycocalyx and tight and adherens junctions with severity of plasma leakage in dengue infection215The Journal of Infectious Diseases992999
1. EJTchetgen Tchetgen
2014A general regression framework for a secondary outcome in case-control studies15Biostatistics117128
1. KMTomashek
2. BWills
3. LCSee Lum
4. LThomas
5. ADurbin
6. YSLeo
7. NBosch
8. ERojas
9. KHendrickx
10. MErpicum
11. LAgulto
12. TJaenisch
13. HTissera
14. PSuntarattiwong
15. BACollers
16. DWallace
17. ACSchmidt
18. APrecioso
19. FNarvaez
20. SJThomas
21. REdelman
22. JBSiqueira
23. MCCassetti
24. WDempsey
25. DJGubler
2018Development of standard clinical endpoints for use in dengue interventional trials12PLOS Neglected Tropical Diseases
1. BVasey
2. AHShankar
3. BBHerrera
4. ABecerra
5. KXhaja
6. MEchenagucia
7. SRMachado
8. DCaicedo
9. JMiller
10. PAmedeo
11. ENNaumova
12. IBosch
13. Norma Blumenfeld deBosch
2020Multivariate time-series analysis of biomarkers from a dengue cohort offers new approaches for diagnosis and prognosis14PLOS Neglected Tropical Diseases
1. NLVuong
2. HTLe Duyen
3. PKLam
4. DTHTam
5. NVVinh Chau
6. NVan Kinh
7. NChanpheaktra
8. LCSLum
9. EPleités
10. NKJones
11. CPSimmons
12. KRosenberger
13. TJaenisch
14. CHalleux
15. PLOlliaro
16. BWills
17. SYacoub
2020C-reactive protein as a potential biomarker for disease progression in dengue: a multi-country observational study18BMC Medicine
1. NLVuong
2. NTHQuyen
3. NTHTien
4. NMTuan
5. DTHKien
6. PKLam
7. DTHTam
8. TVan Ngoc
9. SYacoub
10. TJaenisch
11. RBGeskus
12. CPSimmons
13. BAWills
2021Higher plasma viremia in the febrile phase is associated with adverse dengue outcomes irrespective of infecting serotype or host immune status: an analysis of 5642 vietnamese cases72Clinical Infectious Diseases
1. NLVuong
2021eLife_Biomarkers_Dengue_2021https://archive.softwareheritage.org/swh:1:dir:2208b3484f7b7568f4ecde57bb8f0f641194a6b0;origin=https://github.com/Nguyenlamvuong/eLife_Biomarkers_Dengue_2021;visit=swh:1:snp:531311172177ecad060ca11b9c3752edb33ce261;anchor=swh:1:rev:847d8e0f564eeb3f075b443205fb3384598bc2b4
1. JWhitehorn
2. SYacoub
2019Global warming and arboviral infections19Clinical Medicine149152
1. HWickham
2016Ggplot2: Elegant Graphics for Data AnalysisSpringer-Verlag
1. World Health Organization
2019Strong country capacity, improved tools and community engagement critical to enhancing dengue prevention and controlhttps://www.who.int/news/item/14-11-2019-strong-country-capacity-improved-tools-and-community-engagement-critical-to-enhancing-dengue-prevention-and-control
1. World Health Organization
2020Dengue and severe denguehttps://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
1. SYacoub
2. SKotit
3. MHYacoub
2011Disease appearance and evolution against a background of climate change and reduced resources369Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences17191729
1. SYacoub
2. PKLam
3. LHMVu
4. TLLe
5. NTHa
6. TTToan
7. NTVan
8. NTHQuyen
9. HTLe Duyen
10. NVan Kinh
11. AFox
12. JMongkolspaya
13. MWolbers
14. CPSimmons
15. GRScreaton
16. HWertheim
17. BWills
2016Association of microvascular function and endothelial biomarkers with clinical outcome in dengue: an observational study214Journal of Infectious Diseases697706
1. SYacoub
2. JMongkolsapaya
3. GScreaton
2016Recent advances in understanding dengue5F1000Research
1. SYacoub
2. PKLam
3. TTHuynh
4. HHNguyen Ho
5. HTDong Thi
6. NTVan
7. LTLien
8. QNTHa
9. DHTLe
10. JMongkolspaya
11. ACulshaw
12. TWYeo
13. HWertheim
14. CSimmons
15. GScreaton
16. BWills
2017Endothelial nitric oxide pathways in the pathophysiology of dengue: a prospective observational study65Clinical Infectious Diseases14531461
1. YKYong
2. HYTan
3. SHJen
4. EMShankar
5. SKNatkunam
6. JSathar
7. RManikam
8. SDSekaran
2017Aberrant monocyte responses predict and characterize dengue virus infection in individuals with severe disease15Journal of Translational Medicine

Combination of inflammatory and vascular markers in the febrile phase of dengue is associated with more severe outcomes

Abstract

Introduction

Materials and methods

Study design

Study population

Study flowchart.

Laboratory evaluation (details in Appendix 1)

Study endpoints (details in Appendix 2)

Statistical analysis (details in Appendix 3)

Results

Patient characteristics

Summary of clinical data by primary outcome.

Biomarker levels

Biomarker levels by groups.

Associations between biomarker levels and the endpoints

Results from models for the primary endpoint (severe or moderate dengue).

Results from models for the primary endpoint (severe or moderate dengue).

Best combinations of biomarkers associated with the primary endpoint

Best combinations of biomarkers associated with severe or moderate dengue for children.

Best combinations of biomarkers associated with severe or moderate dengue for adults.

Discussion

References